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Abstract
We describe aggressive immunosuppressive treatment of an adolescent with Susac's syndrome
(SS), a disease of the microvasculature in the brain, retina, and inner ear. Because the
immunopathogenesis of SS appears to have much in common with that of juvenile dermatomyositis
(JDM), the patient was treated with an approach that has been effective for severe JDM. The
patient's outcome provides evidence for the importance of prompt, aggressive, and sustained
immunosuppressive treatment of encephalopathic SS.
Introduction
Susac's syndrome (SS), which consists of the clinical triad
of encephalopathy, branch retinal artery occlusion
(BRAO), and hearing loss (HL), appears to be due to
autoimmune endotheliopathy in the microvasculature of
the brain, retina, and inner ear [1,2]. Resultant ischemic
injury produces pathognomonic central corpus callosal
"holes" (infarcts) on MRI [3], retinal infarcts that are asso-
ciated with a distinctive multifocal staining on fluorescein
retinal angiography [4], and HL that is often accompanied
by roaring tinnitus and vertigo.
The immunopathogenesis of SS [1,2,5-9] appears to have
much in common with that of juvenile dermatomyositis
(JDM) [10-13], an autoimmune endotheliopathy that
affects the microvasculature of a different triad of tissues
(muscle, skin, and gastrointestinal tract). We report a 16
year old female with encephalopathic SS who was success-
fully treated with a protocol [2,14] based on aggressive
treatment of severe dermatomyositis [13,15].
Case presentation
Over a period of two weeks in January 2005, a 16 year old
Caucasian female developed incapacitating headaches,
recurrent vomiting, visual disturbance ("seeing round,
dark black spots"), hearing loss, roaring tinnitus, slurred
speech, unsteady gait, mild neck stiffness, confusion,
short term memory deficit, slow thought processing, emo-
tional lability, personality change, and a tendency to sleep
excessively.
When seen 2 weeks into the course of her illness, her vis-
ual acuity was 20/20 OU, but dilated ophthalmologic
examination revealed a subtle "cotton wool" spot in her
right eye. Though tired and mildly lethargic, she con-
versed normally and was able to provide her own history.
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Her gait was unsteady. She had bilateral long tract find-
ings and difficulty performing rapid alternating move-
ments, particularly on the left. The rest of her physical
exam was normal.
MRI of the brain showed numerous widespread small
hyperintense white matter lesions on T2 and FLAIR in
both the supratentorial and infratentorial compartments.
Several of these lesions enhanced, and there was impres-
sive leptomeningeal enhancement cloaking the cerebral
and cerebellar hemispheres. The central corpus callosum
was extensively involved (Figure 1). Similar lesions were
present in the basal ganglia. Diffusion weighted images
showed restriction in many of these lesions.
Cerebrospinal fluid examination revealed an elevated
protein (166 mg/dl), mild pleocytosis (11 WBC/dl, all
lymphocytes), and an elevated myelin basic protein
(28.54 ng/ml, with upper limit being 4.1 ng/ml). The CSF
IgG index was normal. There were no oligoclonal bands.
Her ESR, CRP, ANA, rheumatoid factor, muscle enzymes,
and anti-phospholipid antibodies were normal or nega-
tive. Von Willebrand Factor-Antigen (VWF-Ag) and Factor
VIII levels were not obtained prior to initiation of corti-
costeroid therapy, but were subsequently repeatedly ele-
vated, as high as 530% and 330%, respectively (with
normal being 50–150%). Early in her course she had mild
thrombocytopenia (99,000–117,000). Fluorescein retinal angiography showed a pattern com-
patible with resolved BRAO in the right eye and also
revealed multifocal arteriolar disease in the retinal periph-
ery. Audiograms (Figure 2) showed bilateral low fre-
quency sensorineural hearing loss. Speech discrimination
was impaired.
Formal neuropsychological evaluation revealed a Full
Scale IQ of 104. Her estimated pre-morbid IQ was 121.
She had poor verbal fluency, mild aphasia, short term
memory deficits, slow processing speed, and executive
dysfunction.
Although the MRI findings were initially thought to repre-
sent "atypical ADEM (acute disseminated encephalomy-
elitis)" or "atypical MS (multiple sclerosis)," the central
location of the corpus callosal lesions, the involvement of
the basal ganglia, and the presence of leptomeningeal
enhancement led to a correct diagnosis of SS, especially
when these MRI findings were coupled with the BRAO
and HL.
She was aggressively treated as shown in Figure 3. Initially,
she received high dose oral prednisone, frequent pulses of
methylprednisolone, monthly IVIG, and monthly pulses
of IV cyclophosphamide. After receiving 6 monthly pulses
of cyclophosphamide, she was placed on mycophenylate
mofetil (MM) for maintenance therapy. However, since
Audiogram Figure 2
Audiogram. Audiogram showing bilateral low frequency 
hearing loss, rising to normal at higher frequencies. This is 
the typical (cochlear) hearing loss seen in SS. It likely reflects 
microinfarction of the striae vascularis at the apex of the 
cochlea. (X = left ear; O = right ear.)
MRI brain Figure 1
MRI brain. Axial T2 image showing multiple white matter 
lesions, especially in the corpus callosum. The arrows point 
to only two of several callosal lesions. Early in the disease, 
callosal lesions are usually best seen on thin section sagittal 
FLAIR and sagittal T1 images, with contrast.Pediatric Rheumatology 2008, 6:3 http://www.ped-rheum.com/content/6/1/3
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she was unable to tolerate side effects of MM (malaise and
nausea), pulse cyclophosphamide therapy was resumed.
Not shown in Figure 3 is a single dose of natalizumab that
she received during the first week of treatment. Shortly
after that single dose, we decided that the risk/benefit
ratio for natalizumab did not justify further doses. Since
then, we have not used natalizumab for this patient or any
subsequent SS patients.
Clinical Course and Outcome
The patient has now been followed for 36 months (156
weeks). Within two days after onset of treatment her head-
ache and vomiting resolved, and her encephalopathy
began to improve. Her encephalopathy continued to
steadily improve thereafter and has never relapsed. Repeat
neuropsychological evaluation at week 41 revealed a full
scale IQ of 122 and a return to pre-morbid estimates in
many domains. Fifty two weeks after onset of treatment
she scored in the 98th percentile on her college entrance
examination. Repeat MRI at 60 weeks revealed marked
resolution of the previously noted white matter lesions.
Her corpus callosum was thinned and showed the typical
residual callosal "holes" of SS (Figure 4).
Her BRAO quickly resolved without further visual com-
plaints and without recurrence. Her vision at 41 weeks
was 20/20 OU, with only a tiny asymptomatic field defect
in the right eye. Her audiogram improved modestly dur-
ing the first two weeks of treatment, but has not changed
since that time. Her tinnitus was very distressing during
the first 8 weeks, but has been quite tolerable since.
Her cyclophosphamide, IVIG and methotrexate were suc-
cessfully tapered and discontinued by week 72. Pulses of
methylprednisolone were gradually given less frequently
and discontinued by week 84. She was tapered off of pred-
nisone by the end of week 104 and has been on no medi-
cations since then.
At last follow-up (36 months) she still had residual,
unchanged hearing loss and mild tinnitus, but her over-all
neuropsychological status was better than that docu-
mented at week 41. She still had subtle short term mem-
ory difficulty and mild difficulty with executive function,
but both of these problems had not changed since discon-
tinuation of medication and appeared to represent resid-
ual deficits. No other residual deficits from her SS were
evident.
Immunosuppressive therapy Figure 3
Immunosuppressive therapy. Graphic depiction of the patient's immunosuppressive treatment.Pediatric Rheumatology 2008, 6:3 http://www.ped-rheum.com/content/6/1/3
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Although we and the family did not think there was any
ongoing active disease at the 3 year mark, the patient was
struggling, emotionally, to cope with her permanent hear-
ing loss and the above-mentioned residual cognitive defi-
cits. These residual deficits have been heartbreaking and
of great concern to the family. For this reason, we and the
family feel her outcome has been good, but not excellent.
Despite her residual deficits and the emotional challenges
they have created, she is currently succeeding in a high
honors curriculum in the humanities at a major univer-
sity.
Discussion
Our patient is the third reported pediatric patient who has
experienced all three components of the SS triad. Hahn
reported SS in a 16 year old female [16]; Muttikkal in a 9
year old girl [17]. Delaney reported an 8 year old child
who had BRAO and hearing loss, but no clinically evident
encephalopathy [18]. Of the approximately 80 cases of SS
that have been reported in the international medical liter-
ature since Dr. Susac's first report in 1979, our patient rep-
resents only the second case of SS (adult or pediatric)
reported in the rheumatologic literature [19]. Although
elevated VWF-Ag levels have not been reported in SS, one
report has mentioned elevated Factor VIII levels [8].
Thrombocytopenia has not been mentioned in any previ-
ous reports on SS.
Patients with SS often do not exhibit the complete triad at
the beginning of their illness. Encephalopathy, BRAO,
and hearing loss can each be the sole presenting manifes-
tation of SS, with the other two components evolving
later. Some patients with SS never develop clinical evi-
dence of all 3 components of the triad.
Patients with SS are commonly mistakenly thought to
have either "atypical multiple sclerosis (MS)" or "atypical
ADEM." Several realizations can help the physician to dis-
tinguish SS from these two disorders [3]: In MS and
ADEM the callosal involvement is along the undersurface
of the callosum at the septal interface; while in SS the cen-
tral fibers of the corpus callosum are primarily affected.
Leptomeningeal enhancement, which occurs in 33% of
patients with SS, does not occur in MS or ADEM. Deep
gray matter involvement is rare in MS, though common in
pediatric ADEM. Deafness is rare in MS and has not been
reported in ADEM. True BRAO is incompatible with a
diagnosis of MS, and has not been reported in ADEM.
SS should also be considered when a patient presents with
an enigmatic encephalopathy (including encephalopathy
with a predominance of psychiatric manifestations), or
visual disturbance, or hearing loss (or combinations of
these three) and has a working diagnosis of "possible neu-
ropsychiatric lupus," "possible primary angiitis of the
CNS," "unusual Meniere's disease," "autoimmune inner
ear disease (AIED)," "possible Cogan's syndrome," "pos-
sible CNS (or retinal) vasospasm," "possible CNS (or ret-
inal) embolism/thrombosis," or "unexplained branch
retinal artery occlusion."
When SS is a consideration, it is essential to obtain an MRI
of the brain and focus on the corpus callosum. Early in the
disease, the typical callosal lesions are best seen on thin-
section sagittal FLAIR and sagittal T1 (with contrast)
images of the corpus callosum. Even if the patient has no
obvious hearing loss or visual symptoms, it is important
to obtain an audiogram and to consult a neuro-ophthal-
mologist/retinal specialist. Even if a careful fundoscopic
exam is normal, we strongly urge fluorescein retinal angi-
ography to look for asymptomatic retinal vasculopathy.
When the angiography is performed, it is particularly
important to include a careful look at the retinal periph-
ery.
Brain biopsies, anatomical observations, and responses to
immunosuppressive therapy suggest that SS is a primary
autoimmune microvascular endotheliopathy: Most
reports on brain biopsies of patients with SS have empha-
sized the finding of small foci of necrosis (microinfarcts)
within the cerebral cortex and white matter. Unfortu-
nately, only a few reports have provided detailed informa-
tion about the microvasculature [5-9]. Fox reported a
microangiopathy characterized by adventitial thickening
and endothelial swelling in precapillary arterioles, thick-
ening of the basal lamina, and a perivascular infiltrate in
small vessels [5]. Heiskala reported that "the walls of sev-
eral small arterioles were thickened and surrounded by an
abnormal reticulin network and occasional lymphocytes;
the normal capillary network was destroyed; and electron
MRI brain Figure 4
MRI brain. Sagittal T1 image showing the pathognomonic 
central callosal "holes" (microinfarcts) of SS. These residual 
"holes" (and sometimes, "spokes") develop as the acute cal-
losal changes resolve.Pediatric Rheumatology 2008, 6:3 http://www.ped-rheum.com/content/6/1/3
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micrographs showed a remarkably thick basal lamina in
many capillaries, both in the cerebral cortex and white
matter [6]." Kaminska described "arteriolar wall prolifera-
tion with lymphocytic infiltration of the vessel wall [7]."
Petty described "minimal perivascular lymphocytic infil-
tration without fibrinoid necrosis or necrotizing vasculitis
[8]."
Petty performed muscle biopsies on 5 patients with SS
and described "swollen endothelial cells and sparse peri-
arteriolar inflammatory cells" in three [8]. "The swollen
endothelial cells nearly occluded some small arterioles."
Similarly, in a muscle biopsy of a patient with SS, O'Hal-
loran described "occluded endomysial capillaries" and
"foci of C5b-9 within the walls of small arterioles [9]."
None of these patients had clinical evidence of muscle dis-
ease. Petty and others have suggested that the same micro-
vascular endotheliopathy that is occurring (subclinically)
in the muscle of patients with SS is also occurring in the
brain, retina, and inner ear [8].
The above-described histopathologic and electron micro-
scopic findings in the microvasculature of the brain and
muscle of patients with SS are quite reminiscent of the
microvascular abnormalities seen in the skin and muscle
of children with juvenile dermatomyositis (JDM). For
example, documented characteristics of the microvascular
endotheliopathy of JDM include: endothelial cell swell-
ing, sometimes to the point of lumenal occlusion;
endothelial cell degeneration and necrosis; capillary net-
work destruction ("drop-out"); basement membrane
thickening, reduplication, and lamellation; granular C5b-
9 deposition in blood vessels; and perivascular lym-
phocytic infiltration [10-12]. Interestingly, in JDM, micro-
vascular endotheliopathy has also been noted (rarely) in
the brain and retina [20,21]. For example, in JDM, the
same endothelial cell swelling and endothelial cell necro-
sis that is seen in the muscle, skin, and GI tract has been
noted (rarely) in the microvasculature of the brain [20].
Spectacular multifocal branch retinal artery staining on
fluorescein angiography has also been seen in JDM [21].
And, transient retinal exudates and "cotton wool" spots,
with temporary loss of vision, have been described in JDM
[22].
In SS, the findings on fluorescein retinal angiography pro-
vide strong support for the notion that endothelial injury
plays a central role in the pathogenesis of SS. The multifo-
cal fluorescein staining/leakage localizes the site of
immune attack to the endothelium of the precapillary
arteriole (less than 100 microns), a site that consists pri-
marily of endothelium and basement membrane. The ele-
vated VWF-Ag and Factor VIII levels seen in our patient
also provide evidence for endothelial cell perturbation in
SS.
SS and JDM, therefore, have several characteristics in com-
mon. Both represent microvascular endotheliopathies
that cause ischemic insult to a triad of tissues – primarily
skin, muscle, and gastrointestinal tract in dermatomyosi-
tis; primarily brain, retina, and cochlea in SS. Both have
biopsy findings characterized by endothelial cell injury in
microvasculatures. Elevated VWF-Ag and Factor VIII levels
have been detected in both diseases. Both follow variable
courses [1,2,13,23,24]. In both cases, the disease may fol-
low a 6–24 month duration monocyclic course (encepha-
lopathic variety in SS), a polycyclic course (the recurrent
BRAO/HL subset in SS), or a prolonged chronic continu-
ous course (rare in SS). Both respond to immunosuppres-
sive medication [1,2,13-15,23,24]. Finally, in SS,
microvascular endotheliopathy can be found in muscle
[5]; and, in JDM, microvascular endotheliopathy can be
found in brain and retina [20,21].
Because SS and JDM appear to have much in common, we
suggest that lessons learned from study of the immun-
opathogenesis, clinical course and treatment of JDM may
be applicable to SS. With this in mind, we treated our
patient with an aggressive immunosuppressive approach
[2,14] that has been effective for severe JDM [13,15].
Although we believe her treatment served her very well,
the varied and only somewhat predictable natural history
of SS makes it difficult to know exactly how much credit
her treatment should be given for suppressing and main-
taining control over her disease. To date, our knowledge
of the natural history of SS and its responsiveness to treat-
ment is based entirely on anecdotal case reports and retro-
spective analysis of short series of patients [1,2,5-
9,14,16,17,23]. No controlled studies of treatment have
been conducted.
Analysis of reported cases reveals that some patients with
SS, despite receiving no immunosuppressive treatment,
have experienced a monocyclic course that has remitted
spontaneously and resulted in good clinical outcome.
(Such cases initially suggested that SS might not be an
autoimmune disorder.) Other patients have seemed to
respond dramatically to corticosteroid therapy – strongly
suggesting that SS is an autoimmune disorder. Others
have failed to respond adequately to corticosteroid ther-
apy, but have seemed to respond well to cyclophospha-
mide – suggesting that SS sometimes needs more than just
corticosteroid therapy. Some patients have failed to
respond to both corticosteroid and cyclophosphamide
therapy – suggesting that some patients may have such
severe disease that usual corticosteroid and cyclophospha-
mide therapy may be inadequate. Many patients have
responded well to immunosuppressive therapy, but have
relapsed (either spontaneously or when immunosuppres-
sive therapy has been tapered too quickly), and have againPediatric Rheumatology 2008, 6:3 http://www.ped-rheum.com/content/6/1/3
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responded to reinstitution or escalation of immunosup-
pression.
The above case reports are reminiscent of what is known
about the natural history of JDM and the spectrum of
responsiveness of JDM to various immunosuppressive
therapies. It is wise to recall that in the pre-steroid era, a
third of JDM patients recovered fully without any treat-
ment, a third experienced chronic disability, and a third
died. It is also important to realize that the prompt,
aggressive, and sustained immunosuppressive treatment
that children with JDM now receive has resulted in a
marked improvement in outcome [15]. At the current
time, there is still a spectrum regarding how much immu-
nosuppressive medication JDM requires (and for how
long). The same is probably true for SS. Clearly, careful
collaborative study of as large a number of patients as pos-
sible will be necessary to determine optimal treatment of
SS.
In the meantime, we encourage prompt, aggressive, and
sustained immunosuppressive treatment of SS. We think
such treatment may prevent or minimize the feared seque-
lae of dementia, vision loss, and hearing loss. We suspect
that, historically, encephalopathic SS has often been
treated too late, with too little, and/or for too short a time.
Historically, this was the case with JDM, too. We strongly
encourage international collaborative study of SS to fur-
ther test the hypothesis that the immunopathogenesis of
SS is similar to that of JDM, and to determine optimal
treatment. Our goal should be excellent outcome, not just
good outcome. Until more is known, we offer the proto-
col depicted in Figure 3 and detailed elsewhere [2,14] as a
tentative model for treatment of encephalopathic SS.
Finally, since SS appears to be an immune-mediated dis-
ease with immunohistopathologic characteristics similar
to those seen in JDM and requires long-term immunosup-
pressive therapy, we urge the international rheumatology
community to become more aware of SS, to view it as an
autoimmune disease, and to become more involved in its
diagnosis, treatment, and study.
Conclusion
Susac's syndrome, which consists of the clinical triad of
encephalopathy, branch retinal artery occlusion, and
hearing loss, appears to represent an autoimmune
endotheliopathy in the microvasculature of the brain, ret-
ina, and inner ear (sometimes with subclinical involve-
ment of muscle). The immunopathogenesis may have
much in common with that of juvenile dermatomyositis,
an autoimmune endotheliopathy that causes ischemic
injury in a different triad of tissues – muscle, skin, and gas-
trointestinal tract (and, rarely, brain and retina). Because
of these similarities, we believe that lessons learned from
study of the immunopathogenesis, clinical course, and
treatment of JDM may be applicable to SS. Accordingly,
we treated our patient with an aggressive immunosup-
pressive approach that has been effective for severe JDM.
She appeared to benefit considerably from this treatment.
We strongly encourage international collaborative study
of SS to further test the hypothesis that the immun-
opathogenesis of SS is similar to that of JDM and to deter-
mine optimal treatment. In the meantime, we encourage
prompt, aggressive, and sustained treatment of SS, and we
offer the protocol depicted in Figure 3 as a tentative model
for treatment of encephalopathic SS.
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